1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Terumo Corporation
  6. News
  7. Summary
    4543   JP3546800008


Delayed Japan Exchange  -  02:00 2022-08-18 am EDT
4615.00 JPY   -2.31%
08/12TERUMO : Q&A Session at the Financial Results Briefing for the First Quarter of FYE 3/2023 (PDF 204.5 KB)
08/10TERUMO : Financial Results for the FYE 3/2023(with note) (PDF 1 MB)
08/10Japanese Shares Slide for Second Straight Day; Olympus Logs 33% Jump in Fiscal Q1 Attributable Profit
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NHS England chooses Spectra Optia(R) Apheresis System as part of MedTech Funding Mandate for expansion of sickle cell disease treatment

06/16/2022 | 12:49pm EDT

* Adoption of Terumo Blood and Cell Technologies' Spectra Optia will save the UK's NHS an expected GBP 13 million per year[1]

Lakewood, Colorado, US -- Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies, today announces the UK's NHS England has selected the automated red blood cell exchange (RBCX) procedure performed on the company's Spectra Optia(R) Apheresis System through the NHS MedTech Funding Mandate (MTFM) to treat sickle cell disease. As a result of this decision, Spectra Optia will be deployed more widely in hospitals across England. This will enable sickle cell disease patients to have improved access to this life-changing treatment.

"Sickle cell disease (SCD) is a group of inherited red blood cell disorders that can result in unbearable pain and the need for emergency hospitalization," said Antoinette Gawin, CEO, Terumo Blood and Cell Technologies. "Specific ethnic minorities suffering from sickle cell disease are an underserved group of patients due to historical health inequalities. We have used Spectra Optia to target sickle cell disease to help address some of these inequalities. Existing standards of care for sickle cell disease vary by region in England and often come with additional health complications that lead to higher costs and poor health outcomes. The NHS MedTech Funding Mandate will enable our Spectra Optia system to be used to help treat more patients across England far more cost-effectively."[1]

Sickle cell disease is one of the most common genetic conditions affecting people in England.[2] There are currently over 12,000 patients receiving treatment in 68 different NHS hospitals. Forty percent of those patients are under 20 years old. [3]

"Currently, many of these patients have to travel far for treatments which take a considerable time to administer, are often painful, and can cause serious side effects.[1] The expansion of the automated red blood cell exchange procedure performed on Terumo's Spectra Optia Apheresis System across England will enable a considerable number of patients to access more effective and cost-effective treatment," said John James, Chief Executive, Sickle Cell Society UK.

The NHS MedTech Funding Mandate was initiated in April 2021. In its first year, it supported four cost-saving technologies approved by the National Institute for Health and Care Excellence (NICE). This support is renewed annually to ensure the technologies meet the policy criteria. In its second year, effective 1 April 2022, the MTFM policy expanded to include seven further technologies, across a variety of clinical conditions, with potential savings of GBP 4 million. All the selected products enable high quality outcomes from treatment and depend on fewer resources, reducing theatre time and length of stay so that more patients across England can be treated more quickly.

Matt Whitty, Chief Executive of Accelerated Access Collaborative and Director of Innovation, Research and Life Sciences at NHS England and NHS Improvement, comments on the MedTech Funding Mandate Policy: "Through research and innovation we can improve patient outcomes. By supporting patients and providers to have equal access to transformative innovations and technologies and by removing barriers to adoption we will reduce health inequalities and improve equity of access for all, and in particular those patients in disproportionately affected groups."

Treatment of sickle cell disease using Spectra Optia technology is estimated to save the NHS GBP 13 million per annum compared to current treatments, including manual RBCX and top-up transfusions.[1] This savings, an estimated GBP 18,100 per patient per year, comes in part because current treatments can lead to iron overload, which can have serious long-term consequences. Iron overload must in turn be treated with chelation therapy, poorly tolerated by some patients. Spectra Optia will mitigate these challenges faced by the NHS and patients by reducing the need for iron chelation therapy and automating the RBCX process for faster treatment.

Terumo Blood and Cell Technologies' Spectra Optia technology received NICE Medical Technology Guidance approval in March 2016 and was reapproved in August 2020.

[1] https://www.nice.org.uk/guidance/mtg28/chapter/2-The-technology

[2] https://cks.nice.org.uk/topics/sickle-cell-disease/background-information/prevalence/#:~:text=Sickle%20cell%20disease%20is%20estimated,conditions%20affecting%20people%20in%20England.

[3] https://nhr.mdsas.com/wp-content/uploads/2022/03/NHR_DataReport2021.pdf


About NHS MedTech Funding Mandate

The MedTech Funding Mandate (MTFM) is an NHS Long Term Plan commitment to get selected NICE-approved cost- saving devices, diagnostics and digital products to NHS patients more quickly. The policy launched on 1 April 2021. After the first year of the new policy, additional guidance was published for 2022/23.

Spectra Optia(R) Apheresis System

The Spectra Optia system is a user-friendly, versatile, industry-leading therapeutic apheresis, cell processing and cell collection platform that allows operators to spend more time focusing on patient care. Therapeutic apheresis is used widely for a variety of applications. For example, practitioners use red blood cell exchange (RBCX) for sickle cell disease treatment; cell collections for stem cell transplantations and to collect starting material for cell therapies; and therapeutic plasma exchange (TPE) to treat many diseases in both the chronic and acute setting in the neurology, nephrology and hematology spaces.

Product and protocol availability varies by country.

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

Media Contacts:

IB Communications

Neil Hunter / Michelle Boxall

Tel +44 (0)20 89434685

neil@ibcomms.agency / michelle@ibcomms.agency


(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

08/12TERUMO : Q&A Session at the Financial Results Briefing for the First Quarter of FYE 3/2023..
08/10TERUMO : Financial Results for the FYE 3/2023(with note) (PDF 1 MB)
08/10Japanese Shares Slide for Second Straight Day; Olympus Logs 33% Jump in Fiscal Q1 Attri..
08/10Terumo's Fiscal Q1 Attributable Profit Falls 20% on Operating Expenses
08/09TRANSCRIPT : Terumo Corporation, Q1 2023 Earnings Call, Aug 09, 2022
08/09TERUMO : Financial Results for the First Quarter of FYE 3/2023 (PDF 1.06 MB)
08/09TERUMO : 1st Quarter Financial Results for FYE 3/2023 (PDF 384.33 KB)
08/09Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending Mar..
08/09Terumo Corporation Provides Dividend Guidance for the Full Year Ending March 31, 2023
08/09Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending M..
More news
Analyst Recommendations on TERUMO CORPORATION
More recommendations
Sales 2023 782 B 5 791 M 5 791 M
Net income 2023 103 B 760 M 760 M
Net Debt 2023 3 725 M 27,6 M 27,6 M
P/E ratio 2023 33,7x
Yield 2023 0,80%
Capitalization 3 488 B 25 819 M 25 819 M
EV / Sales 2023 4,46x
EV / Sales 2024 4,05x
Nbr of Employees 28 294
Free-Float 95,3%
Duration : Period :
Terumo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERUMO CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 4 615,00 JPY
Average target price 5 090,71 JPY
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Shinjiro Sato Senior Executive Officer
Naoki Muto Chief Financial & Accounting Officer
Toshiaki Takagi Chairman
Katsuya Takeuchi Chief Information Officer & Executive Officer
Kazuhisa Senshu Chief Clinical & Regulatory Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-8.26%126 108